SCHEMBL3007526

SCHEMBL3007526

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
ALDH1A1 P00352 5/20 0.39
LMNA P02545 4/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 1/20 0.39
PTPRB P23467 1/20 0.39
GAA P10253 1/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
GPR6 P46095 1/20 0.35
CES2 O00748 1/20 0.35
F2RL3 Q96RI0 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008408 0.91 F2RL3 (0.36) ALDH1A1F2RL3SMN1; SMN2
SCHEMBL3000434 0.91 RAB9A (0.38) MAPTALDH1A1KMT2AMEN1F2RL3
SCHEMBL3019284 0.89 DNM1L (0.35) MAPTALDH1A1
SCHEMBL3008973 0.89 FABP4 (0.38) ALDH1A1LMNATSHRKMT2A
SCHEMBL3012900 0.89 DNM1L (0.37) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL3013521 0.87 RAB9A (0.36) MAPTMAPK1KMT2AF2RL3SMN1; SMN2
SCHEMBL3017918 0.87 RAB9A (0.36) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3007049 0.87 F2RL3 (0.36) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL3017999 0.86 MAPT (0.47) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3008927 0.86 MAPT (0.42) MAPTALDH1A1LMNAHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.